Literature DB >> 10480155

Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors.

P Ureña1, M C Malergue, B Goldfarb, P Prieur, C Guédon-Rapoud, M Pétrover.   

Abstract

Cardiovascular diseases represent the major cause of death in hemodialysis patients. However, little information is available about the repercussion of uremia on cardiac valves. We retrospectively investigated the incidence rate of aortic stenosis (AS), from 1991 to 1996, in 110 hemodialysis patients followed by Doppler-echocardiography. Progressive AS was diagnosed in 16 patients who had a decrease in their indexed aortic valve area from 1.24 +/- 0.09 to 0.66 +/- 0.21 cm2/m2 of BSA in 16.8 +/- 1.9 months. The mean incidence of AS per year was of 3.3%, ranging from 1.5 to 8.0%. Eight patients died in less than 3 years after the diagnosis of AS with a mean survival time of 23.0 +/- 9.5 months. Survival curves using Kaplan-Meier estimates showed a statistically significant decrease in the survival rate of patients with AS compared with patients without valvulopathy (p < 0.001). They were older than patients with normal valve, 68.6 +/- 11.1 versus 56.7 +/- 16.0 years, respectively. Men were 4 times more affected than women and showed a significantly more rapid progression to AS than women. The calcium-phosphorus product was higher in AS patients, 5.43 +/- 0.98 than in patients without AS, 3.95 +/- 0.50 mM. It was mainly due to hyperphosphatemia without hypercalcemia and the hyperphosphatemia was associated with biological signs of hypoparathyroidism or adynamic bone disease in 62% of the cases. Plasma vitamin D3 was also higher in patients with AS, 20.5 +/- 13.5 ng/ml than in those with normal valves, 9.6 +/- 6.3 ng/ml. Logistic regression showed that age, vitamin D3 and hyperphosphatemia correctly predicted 56% of the AS cases. In conclusion, AS is frequent and of poor outcome in hemodialysis patients. Age, relatively high plasma vitamin D3 levels, and hyperphosphatemia, mostly due to hypoparathyroidism, must be considered as risk factors.

Entities:  

Mesh:

Year:  1999        PMID: 10480155

Source DB:  PubMed          Journal:  Nephrologie        ISSN: 0250-4960


  24 in total

1.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

2.  Myocardial calcinosis in chronic renal failure.

Authors:  Ashley E Kempf; Maryam Golshan Momeni; Farhood Saremi
Journal:  J Radiol Case Rep       Date:  2009-02-01

Review 3.  Mineral metabolism and cardiovascular disease in CKD.

Authors:  Hideki Fujii; Nobuhiko Joki
Journal:  Clin Exp Nephrol       Date:  2017-01-06       Impact factor: 2.801

4.  Survival of kidney transplantation patients in the United States after cardiac valve replacement.

Authors:  Alok Sharma; David T Gilbertson; Charles A Herzog
Journal:  Circulation       Date:  2010-06-14       Impact factor: 29.690

Review 5.  Selection of artificial valve for the patients on hemodialysis.

Authors:  Hirofumi Takemura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-12-07

Review 6.  Assessment of cardiac structure and function in kidney failure: understanding echocardiography and magnetic resonance imaging for the nephrologist.

Authors:  Dharmenaan Palamuthusingam; Reza Reyaldeen; David Wayne Johnson; Camel M Hawley; Elaine M Pascoe; Sudhir Wahi; Magid Fahim
Journal:  Int Urol Nephrol       Date:  2020-08-31       Impact factor: 2.370

7.  Late calcific mitral stenosis after MitraClip procedure in a dialysis-dependent patient.

Authors:  Nicolas H Pope; Scott Lim; Gorav Ailawadi
Journal:  Ann Thorac Surg       Date:  2013-05       Impact factor: 4.330

8.  Transcatheter or surgical aortic valve implantation in chronic dialysis patients: a German Aortic Valve Registry analysis.

Authors:  Gloria Färber; Sabine Bleiziffer; Torsten Doenst; Dimitra Bon; Andreas Böning; Helge Weiler; Eva Herrmann; Christian Frerker; Andreas Beckmann; Helge Möllmann; Stephan Ensminger; Raffi Bekeredjian; Thomas Walther; Wolfgang Harringer; Hugo A Katus; Christian W Hamm; Friedhelm Beyersdorf; Timm Bauer; Stephan Fichtlscherer
Journal:  Clin Res Cardiol       Date:  2020-09-23       Impact factor: 5.460

9.  Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

Authors:  Steven Fishbane; Warren B Shapiro; Dalila B Corry; Steven L Vicks; Michael Roppolo; Kenneth Rappaport; Xiang Ling; William G Goodman; Stewart Turner; Chaim Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

10.  ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model.

Authors:  Mikko A Simolin; Tanja X Pedersen; Susanne Bro; Mikko I Mäyränpää; Satu Helske; Lars B Nielsen; Petri T Kovanen
Journal:  BMC Cardiovasc Disord       Date:  2009-03-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.